NW-1689

NW-1689 is a process-related impurity of safinamide mesilate (SAFM), which is a medication used in the treatment of Parkinson's disease (PD) . SAFM acts as a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium and N-type calcium channels. These actions assist in reducing dopamine breakdown and suppressing glutamate release. NW-1689 shares structural similarities with SAFM and exhibits comparable pharmacological effects, making it applicable in Parkinson's disease research.